AC Immune (ACIU) 6-K 6 Aug 24 Current report (foreign) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2024
Cover [Abstract]
Document Type	6-K
Entity Registrant Name	AC IMMUNE SA
Entity Central Index Key	0001651625
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Amendment Flag	false
Current Fiscal Year End Date	--12-31

Consolidated Balance Sheets

Consolidated Balance Sheets - CHF (SFr) SFr in Thousands	Jun. 30, 2024	Dec. 31, 2023
Non-current assets
Property, plant and equipment	SFr 2,926	SFr 3,376
Right-of-use assets	3,235	3,508
Intangible asset	50,416	50,416
Long-term financial assets	415	361
Total non-current assets	56,992	57,661
Current assets
Prepaid expenses	3,864	6,437
Accrued income	402	246
Other current receivables	1,153	622
Accounts receivable	0	14,800
Short-term financial assets	123,560	24,554
Cash and cash equivalents	51,564	78,494
Total current assets	180,543	125,153
Total assets	237,535	182,814
Shareholders' equity
Share capital	2,212	2,089
Share premium	476,074	474,907
Treasury shares	(218)	(105)
Currency translation differences	(35)	(51)
Accumulated losses	(354,608)	(316,197)
Total shareholders' equity	123,425	160,643
Non-current liabilities
Long-term deferred contract revenue	5,170
Long-term lease liabilities	2,542	2,825
Net employee defined benefit liabilities	5,868	5,770
Total non-current liabilities	13,580	8,595
Current liabilities
Trade and other payables	1,435	1,679
Accrued expenses	11,895	11,087
Short-term deferred income	45	138
Short-term deferred contract revenue	86,468
Short-term lease liabilities	687	672
Total current liabilities	100,530	13,576
Total liabilities	114,110	22,171
Total shareholders' equity and liabilities	SFr 237,535	SFr 182,814

Consolidated Statements of Inco

Consolidated Statements of Income/(Loss) - CHF (SFr) SFr in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Contract revenues and other operating income
Contract revenue	SFr 687		SFr 687	SFr 0
Total revenue	687		687
Operating expenses
Research & development expenses	(17,138)	SFr (13,682)	(32,303)	(27,555)
General & administrative expenses	(4,551)	(3,681)	(9,522)	(7,787)
Other operating income/(expense), net	41	317	109	725
Total operating expenses	(21,648)	(17,046)	(41,716)	(34,617)
Operating loss	(20,961)	(17,046)	(41,029)	(34,617)
Financial income	739	259	1,368	468
Financial expense	(34)	(27)	(70)	(124)
Exchange differences, net	(2,504)	(16)	(891)	(67)
Finance result, net	(1,799)	216	407	277
Loss before tax	(22,760)	(16,830)	(40,622)	(34,340)
Income tax expense		(3)		(6)
Loss for the period	SFr (22,760)	SFr (16,833)	SFr (40,622)	SFr (34,346)
Loss per share:
Basic loss per share for the period attributable to equity holders	SFr (0.23)	SFr (0.20)	SFr (0.41)	SFr (0.41)
Diluted loss per share for the period attributable to equity holders	SFr (0.23)	SFr (0.20)	SFr (0.41)	SFr (0.41)

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income/(Loss) - CHF (SFr) SFr in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Consolidated Statements of Comprehensive Income/(Loss)
Loss for the period	SFr (16,833)	SFr (40,622)	SFr (34,346)
Items that may be reclassified to income or loss in subsequent periods (net of tax):
Currency translation differences	(8)	16	(16)
Total comprehensive loss (net of tax)	SFr (16,841)	SFr (40,606)	SFr (34,362)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - CHF (SFr) SFr in Thousands	Share capital	Share premium	Treasury shares	Accumulated losses	Currency translation differences	Total
Balance, beginning of period at Dec. 31, 2022	SFr 1,797	SFr 431,323	SFr (124)	SFr (264,015)	SFr 10	SFr 168,991
Net loss for the period				(34,346)		(34,346)
Other comprehensive income/(loss)					(16)	(16)
Total comprehensive loss (net of tax)				(34,346)	(16)	(34,362)
Share-based payments				2,701		2,701
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs		1,997	14			2,011
Issuance of shares, net of transaction costs:
Restricted share awards	3	388		(395)		(4)
Exercise of options		(9)				(9)
Balance, end of period at Jun. 30, 2023	1,800	433,699	(110)	(296,055)	(6)	139,328
Balance, beginning of period at Dec. 31, 2023	2,089	474,907	(105)	(316,197)	(51)	160,643
Net loss for the period				(40,622)		(40,622)
Other comprehensive income/(loss)					16	16
Total comprehensive loss (net of tax)				(40,622)	16	(40,606)
Share-based payments				3,277		3,277
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs		104	1			105
Issuance of shares to be held as treasury shares	114		(114)
Issuance of shares, net of transaction costs:
Restricted share awards	9	1,057	0	(1,066)		0
Exercise of options	0	6				6
Balance, end of period at Jun. 30, 2024	SFr 2,212	SFr 476,074	SFr (218)	SFr (354,608)	SFr (35)	SFr 123,425

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CHF (SFr) SFr in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities
Loss for the period	SFr (40,622)	SFr (34,346)
Adjustments to reconcile net loss for the period to net cash flows:
Depreciation of property, plant and equipment	767	842
Depreciation of right-of-use assets	337	269
Finance (income), net	110	(132)
Share-based compensation expense	3,277	2,701
Change in net employee defined benefit liability	98	558
Interest expense	68	125
Changes in working capital:
(Increase)/decrease in prepaid expenses	2,574	(471)
(Increase)/decrease in accrued income	(156)	(267)
(Increase)/decrease in accounts receivable	14,800
(Increase)/decrease in other current receivables	(510)	89
(Decrease)/increase in accrued expenses	1,328	(633)
(Decrease)/increase in deferred contract revenue, short-term	86,468
(Decrease)/increase in deferred income	(93)	(157)
(Decrease)/increase in trade and other payables	(246)	433
(Decrease)/increase in deferred contract revenue, long-term	5,170
Cash from/(used in) operating activities	73,370	(30,989)
Interest received	749	197
Interest paid	(60)	(120)
Finance expenses paid	(8)	(5)
Net cash flows from/(used in) operating activities	74,051	(30,917)
Investing activities
Short-term financial assets, net	(99,006)	38,000
Purchases of property, plant and equipment	(317)	(355)
Rental deposits	(54)
Net cash flows (used in)/provided by investing activities	(99,377)	37,645
Financing activities
Proceeds from sale of treasury shares in public offerings, net of underwriting fees and transaction costs	131	2,057
Proceeds from issuance of common shares - equity plan, net of transaction costs	6	(13)
Transaction costs and stamp duty associated with the public offerings of common shares previously recorded in Accrued expenses	(521)
Transaction costs associated with the sale of treasury shares in public offering previously recorded in Accrued expenses	(26)
Principal payments of lease obligations	(340)	(270)
Net cash flows provided by/(used in) financing activities	(750)	1,774
Net increase/(decrease) in cash and cash equivalents	(26,076)	8,502
Cash and cash equivalents at beginning of period	78,494	31,586
Exchange (loss)/gain on cash and cash equivalents	(854)	(81)
Cash and cash equivalents at end of the period	51,564	40,007
Supplemental non-cash activity
Transaction costs associated with the sale of treasury shares in public offering recorded in Accrued expenses	SFr 26	SFr 46

Corporate information

Corporate information	6 Months Ended
	Jun. 30, 2024
Corporate information
Corporate information	Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) (in CHF thousands, except share and per share amounts) 1. Corporate information AC Immune SA was founded in 2003. The Company controls a fully-owned subsidiary, AC Immune USA, Inc. (“AC Immune USA” or “Subsidiary” and, together with AC Immune SA, “AC Immune,” “ACIU,” “Company,” “we,” “our,” “ours,” “us”), which was organized under the laws of Delaware, USA in June 2021. The Company and its Subsidiary form the Group. AC Immune SA is a clinical-stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel proprietary medicines and diagnostics for prevention and treatment of neurodegenerative diseases (NDD) associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of NDD, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), with common mechanisms and drug targets, such as amyloid beta (Abeta), Tau, alpha-synuclein (a-syn) and TDP-43. Our corporate strategy is founded upon a three-pillar approach that targets (i) AD, (ii) focused non-AD NDD including Parkinson’s disease, ALS and NeuroOrphan indications and (iii) diagnostics. We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific small molecules), to discover, design and develop novel medicines and diagnostics to target misfolded proteins. The Interim Condensed Consolidated Financial Statements of AC Immune SA as of and for the three and six months ended June 30, 2024 were authorized for issuance by the Company’s Audit and Finance Committee on August 5, 2024.

Basis of preparation and change

Basis of preparation and changes to the Company's accounting policies	6 Months Ended
	Jun. 30, 2024
Basis of preparation and changes to the Company's accounting policies
Basis of preparation and changes to the Company's accounting policies	2. Basis of preparation and changes to the Company’s accounting policies Statement of compliance These Interim Condensed Consolidated Financial Statements as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023, have been prepared in accordance with International Accounting Standard 34 (IAS 34), Interim Financial Reporting Basis of measurement These Interim Condensed Consolidated Financial Statements have been prepared under the historical cost convention. Functional and reporting currency These Interim Condensed Consolidated Financial Statements and accompanying notes are presented in Swiss Francs (CHF), which is AC Immune SA’s functional currency and the Group’s reporting currency. The Company’s subsidiary has a functional currency of the US Dollar (USD). The following exchange rates have been used for the translation of the financial statements of AC Immune USA: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ Year Ended December 31, ​ ​ 2024 2023 ​ 2024 2023 ​ 2023 CHF/USD Closing rate, USD 1 0.909 0.908 0.909 0.908 0.851 Weighted average exchange rate, USD 1 0.914 0.908 0.898 0.921 0.908 ​ Critical judgments and accounting estimates The preparation of the Company’s Interim Condensed Consolidated Financial Statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions that affect the amounts reported in the Interim Condensed Consolidated Financial Statements and accompanying notes, and the related application of accounting policies as it relates to the reported amounts of assets, liabilities, income and expenses. The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on Licensing and Collaboration Agreements (LCAs), (ii) clinical development accruals, (iii) net employee defined benefit liability, (iv) share-based compensation, (v) right-of-use assets and lease liabilities and (vi) our IPR&D asset (intangible asset). Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Fair value of financial assets and liabilities The Company’s financial assets and liabilities are composed of receivables, short-term financial assets, cash and cash equivalents, trade payables, deferred contract revenue and lease liabilities. The fair value of these financial instruments approximates their respective carrying values due to the short-term maturity of these instruments, and are held at their amortized cost in accordance with IFRS 9, unless otherwise explicitly noted. Accounting policies, new standards, interpretations and amendments adopted by the Company The accounting policies adopted in the preparation of the Interim Condensed Consolidated Financial Statements are consistent with those followed in the preparation of the Company’s annual consolidated financial statements for the year ended December 31, 2023. As of January 1, 2024 the amendments to paragraphs 69 to 76 of IAS 1, Presentation of Financial Statements (IAS 1), as issued by the IASB became effective. The Company assessed the changes to the accounting standard and determined the amendments had an immaterial impact on the Company’s financial statements. There are no other new IFRS standards, amendments or interpretations that are mandatory as of January 1, 2024 that are relevant to the Company. Additionally, in April 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements (IFRS 18). The new standard on presentation and disclosure in the financial statements will change the structure of the statement of profit or loss, require disclosures for certain profit or loss performance measure that are reported outside of the financial statements, and will enhance principles on aggregation and disaggregation within the notes to the financial statements. This new standard will be effective for annual reporting periods beginning on January 1, 2027 and will require retroactive adoption. The Company is currently evaluating the new standard to determine how it will impact the presentation and disclosure in its financial statements. Going concern The Company believes that it will be able to meet all of its obligations as they fall due for at least 12 months from the filing date of this Form 6-K, after considering the Company’s cash position of CHF 51.6 million and short-term financial assets of CHF 123.6 million as of June 30, 2024. Hence, these unaudited Interim Condensed Consolidated Financial Statements have been prepared on a going-concern basis. To date, the Company has financed its cash requirements primarily from its public offerings, share issuances, contract revenues from its LCAs and grants. The Company is a clinical stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company’s business are various risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed and our ability to raise additional capital as needed. These risks may require us to take certain measures such as delaying, reducing or eliminating certain programs. The Company’s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection, (ii) enter into collaborations with partners in the pharmaceutical and biopharmaceutical industries, (iii) successfully move its product candidates through clinical development, (iv) attract and retain key personnel and (v) acquire capital to support its operations.

Contract revenues and other ope

Contract revenues and other operating income	6 Months Ended
	Jun. 30, 2024
Contract revenues and other operating income
Contract revenues and other operating income	3. For the three and six months ended June 30, 2024, AC Immune generated CHF 0.7 million in contract revenue compared with no contract revenue in the prior comparable periods, respectively. ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months ​ ​ Ended June 30, In CHF thousands, unaudited 2024 2023 Takeda 687 — Total contract revenue 687 — ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months ​ ​ Ended June 30, In CHF thousands, unaudited 2024 2023 Takeda 687 — Total contract revenue 687 — ​ ​ 3.1 For a discussion of our licensing and collaboration agreements for the fiscal year ended December 31, 2023, please refer to Note 14.1 “Licensing and Collaboration agreements” of our Annual Report on Form 20-F for the year ended December 31, 2023 filed on March 14, 2024. On January 22, 2024, the Company announced that the development of semorinemab and crenezumab in the collaboration agreements with Genentech, a member of the Roche Group, was terminated. These terminations became effective in April 2024. Anti-Abeta Active Immunotherapy in AD – 2024 agreement Takeda Pharmaceuticals, USA, Inc. In May 2024, the Company entered into a worldwide option and license agreement with Takeda Pharmaceuticals, USA, Inc. (Takeda) for our active immunotherapies targeting Abeta, including ACI-24.060 for the treatment of AD. AC Immune will be responsible for completing the ABATE trial. Following option exercise, Takeda would conduct and fund all further clinical development and be responsible for all global regulatory activities as well as worldwide commercialization. Under the terms of the agreement, AC Immune received an upfront payment of USD 100.0 (CHF 92.3) million in May 2024 and is eligible to receive an option exercise fee in the low-to-mid nine-figure USD range and additional potential development, commercial and sales-based milestones of up to approximately USD 2.1 (CHF 1.9) billion if all related milestones are achieved over the course of the agreement. Upon commercialization, AC Immune will be entitled to receive tiered mid-to-high teens percentages royalties on worldwide net sales. Under the terms of the agreement, Takeda may terminate the agreement at any time by providing 90 days’ notice to the Company. If not otherwise terminated, the agreement shall continue until Takeda decides not to exercise its license option or until the expiration of all royalty obligations as outlined in the contract. AC Immune assessed this arrangement in accordance with IFRS 15 and concluded that Takeda is a customer. The Company identified the following performance obligations under the contract: (i) a license option and (ii) development, chemistry, manufacturing, and controls (“CMC”) and regulatory activities as outlined in the development and CMC plans, which are necessary to deliver the data package to Takeda. AC Immune concluded that the license option is considered a material right, as the value of the license exceeds the option exercise fee, thereby considering it a distinct performance obligation. The development, CMC, and regulatory activities are treated as one distinct performance obligation because the underlying activities are not distinguishable in the context of the contract and are inputs to an integrated development program that will generate valuable data and information for Takeda in determining whether to exercise the option. At the agreement's execution, the transaction price included only the upfront and non-refundable consideration of USD 100.0 (CHF 92.3) million. At inception, none of the development milestones, which may occur prior to the Takeda option exercise, were included in the transaction price, as all milestone amounts were fully constrained. The Takeda option exercise payment and any future development and commercial milestone payments, and royalties following the Takeda option exercise were excluded from the initial transaction price at contract inception. The option exercise fee is considered variable consideration as it depends on Takeda's decision to exercise. In assessing that future development or commercial milestones are fully constrained, the Company considered numerous factors, including that the receipt of these milestones is contingent upon success in future clinical trials and the licensee’s efforts, and thus not highly probable to obtain. Any consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they predominantly relate to the license that will be granted to Takeda upon exercise and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved or other changes in circumstances occur. The valuation of each performance obligation involves estimates and assumptions, with the timing of revenue recognition determined by either delivery or the provision of services. In line with the allocation objective under IFRS 15, the Company allocated the USD 100.0 (CHF 92.3) million upfront payment within the transaction price to the license option and development, CMC, and regulatory activities, using the relative stand-alone selling price method. For the standalone selling price of the license option, the Company utilized an income-based approach, which included key assumptions such as the post-option development timeline and costs, revenue forecasts, discount rates, and probabilities of development and regulatory success. The standalone selling price for the development, CMC and regulatory activities was calculated using a cost-plus margin approach based on the estimated development timeline. The Company allocated the transaction price based on the relative standalone selling prices, assigning USD 87.4 (CHF 80.7) million to the license option and USD 12.6 (CHF 11.6) million to development, CMC, and regulatory activities. The Company has deferred revenue recognition for the license option and will recognize the entirety of the revenue either when the option is exercised and Takeda obtains the exclusive license, or when the option expires. The Company will recognize revenue related to the development, CMC and regulatory performance obligation over the estimated period of completion of these obligations, using an input method reflecting the costs incurred relative to the total costs expected to be incurred. During the three and six months ended June 30, 2024, the Company recorded contract revenue of CHF 0.7 million, reflecting its efforts under this agreement. As of June 30, 2024, the Company recorded CHF 91.6 million in deferred contract revenue related to the unsatisfied performance obligations under this agreement. The deferred contract revenue allocated to the license option is classified as short-term on the condensed consolidated balance sheets because, in accordance with IAS 1, the Company does not have the right to defer the settlement of that portion for at least twelve months after the reporting period. The deferred contract revenue allocated to development, CMC, and regulatory activities will be recognized over the remaining performance period and classified as either current or non-current on the condensed consolidated balance sheets, based on the expected timing of satisfaction of the performance obligations. 3.2 Grants from the Michael J. Fox Foundation For a discussion of our Grants from the Michael J. Fox Foundation (MJFF) for the fiscal year ended December 31, 2023, please refer to Note 14.2 “Grant Income” of our Annual Report on Form 20-F for the year ended December 31, 2023 filed on March 14, 2024. For the three months ended June 30, 2024 and 2023, the Company has recognized less than CHF 0.1 million and CHF 0.3 million in grant income, respectively. For the six months ended June 30, 2024 and 2023, the Company has recognized less than CHF 0.1 million and CHF 0.7 million in grant income, respectively.

Loss per share

Loss per share	6 Months Ended
	Jun. 30, 2024
Loss per share
Loss per share	4. ​ ​ ​ ​ ​ ​ ​ For the Three Months ​ ​ Ended June 30, In CHF thousands except for share and per share data 2024 2023 Loss per share (EPS) Numerator Net loss attributable to equity holders of the Company (22,760) (16,833) Denominator Weighted-average number of shares outstanding used to compute EPS basic and diluted attributable to equity holders 99,549,910 84,612,997 Basic and diluted loss per share for the period attributable to equity holders (0.23) (0.20) ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months ​ ​ Ended June 30, In CHF thousands except for share and per share data 2024 ​ 2023 Loss per share (EPS) ​ Numerator ​ Net loss attributable to equity holders of the Company ​ (40,622) (34,346) Denominator ​ ​ ​ Weighted-average number of shares outstanding used to compute EPS basic and diluted attributable to equity holders ​ 99,467,690 83,654,663 Basic and diluted loss per share for the period attributable to equity holders ​ (0.41) (0.41) ​ The weighted-average number of potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: ​ ​ ​ ​ ​ ​ ​ For the Three Months ​ ​ Ended June 30, ​ 2024 2023 Share options issued and outstanding 1,578,645 97,875 Restricted share awards subject to future vesting 1,631,911 1,213,703 ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months ​ ​ Ended June 30, ​ ​ 2024 ​ 2023 Share options issued and outstanding 1,659,854 97,875 Restricted share awards subject to future vesting 1,684,826 1,225,175 ​

Property, plant and equipment

Property, plant and equipment	6 Months Ended
	Jun. 30, 2024
Property, plant and equipment.
Property, plant and equipment	5. The following table shows the movement in the net book values of property, plant and equipment for the six months ended June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2024 ​ ​ ​ IT Lab Leasehold Assets under ​ In CHF thousands ​ Furniture ​ equipment ​ equipment ​ improvements ​ construction ​ Total Acquisition cost: Balance at December 31, 2023 309 2,168 10,233 1,662 — 14,372 Additions 15 45 214 43 — 317 Balance at June 30, 2024 324 2,213 10,447 1,705 — 14,689 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated depreciation: ​ ​ ​ ​ ​ ​ Balance at December 31, 2023 (212) (1,851) (8,101) (832) — (10,996) Depreciation expense (25) (103) (504) (135) — (767) Balance at June 30, 2024 (237) (1,954) (8,605) (967) — (11,763) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying amount: ​ December 31, 2023 97 317 2,132 830 — 3,376 June 30, 2024 87 259 1,842 738 — 2,926 ​

Right-of-use assets, long-term

Right-of-use assets, long-term financial assets and lease liabilities	6 Months Ended
	Jun. 30, 2024
Right-of-use assets, long-term financial assets and lease liabilities
Right-of-use assets, long-term financial assets and lease liabilities	6. AC Immune recognized additions of less than CHF 0.1 million for its right-of-use of leased assets for the six months ended June 30, 2024. Regarding lease liabilities, the amortization depends on the rate implicit in the contract or the incremental borrowing rate for the respective lease component. The weighted averages of the incremental borrowing rates are 3.5% for buildings, 3.3% for office equipment and 2.6% for IT equipment, respectively. The following table shows the movements in the net book values of right-of-use of leased assets for the six months ended June 30, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Office IT ​ In CHF thousands ​ Buildings ​ equipment ​ equipment ​ Total Balance as of December 31, 2023 3,446 50 12 3,508 Additions and remeasurements — 64 — 64 Depreciation (318) (12) (7) (337) Balance as of June 30, 2024 3,128 102 5 3,235 ​ There are no variable lease payments that are not included in the measurement of lease obligations. All extension options have been included in the measurement of lease obligations. For the three and six months ended June 30, 2024, and 2023, the impact on the Company’s condensed consolidated statements of income/(loss) and the condensed consolidated statements of cash flows is as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months ​ ​ Ended June 30, In CHF thousands 2024 2023 Statements of income/(loss) Depreciation of right-of-use assets 169 134 Interest expense on lease liabilities 29 24 Expense for short-term leases and leases of low value 170 189 Total 368 347 ​ ​ ​ ​ ​ Statements of cash flows ​ Total cash outflow for leases 372 349 ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months ​ ​ Ended June 30, In CHF thousands 2024 2023 Statements of income/(loss) Depreciation of right-of-use assets 337 269 Interest expense on lease liabilities 59 47 Expense for short-term leases and leases of low value 363 488 Total 759 804 ​ ​ ​ ​ ​ Statements of cash flows ​ Total cash outflow for leases 762 805 ​ The following table presents the contractual undiscounted cash flows for lease obligations as of June 30, 2024: ​ ​ ​ ​ ​ ​ As of In CHF thousands June 30, 2024 Less than one year 789 1-3 years 1,550 3-5 years 1,155 Total 3,494 ​ The Company also has deposits in escrow accounts totaling CHF 0.4 million for leases of the Company’s premises as of both June 30, 2024 and December 31, 2023, respectively. These deposits are presented in Long-term financial assets on the Company’s condensed consolidated balance sheets.

Accrued expenses

Accrued expenses	6 Months Ended
	Jun. 30, 2024
Trade and other payables and accrued expenses
Accrued expenses	7. ​ ​ ​ ​ ​ ​ ​ As of In CHF thousands ​ June 30, 2024 ​ December 31, 2023 Accrued expenses 11,895 11,087 Total accrued expenses 11,895 11,087 ​ Accrued expenses consists of accrued R&D costs, accrued payroll expenses and other accrued expenses totaling CHF 11.9 million and CHF 11.1 million as of June 30, 2024 and December 31, 2023, respectively.

Intangible assets

Intangible assets	6 Months Ended
	Jun. 30, 2024
Intangible assets
Intangible assets	8. AC Immune’s acquired IPR&D asset is a clinically-validated active vaccine candidate for the treatment of Parkinson’s disease. The asset is not yet ready for use until the asset obtains market approval and is therefore not currently being amortized. The carrying amount and net book value are detailed below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2024 ​ As of December 31, 2023 ​ Gross ​ ​ Gross ​ ​ ​ ​ Carrying ​ Accumulated ​ Net Book ​ Carrying ​ Accumulated ​ Net Book In CHF thousands ​ Amount ​ Amortization ​ Value ​ Amount ​ Amortization ​ Value Acquired IPR&D asset ​ 50,416 — 50,416 50,416 — 50,416 Total intangible assets ​ 50,416 — 50,416 50,416 — 50,416 ​ In accordance with IAS 36 Impairment of Assets Fair Value Measurement

Prepaid expenses

Prepaid expenses	6 Months Ended
	Jun. 30, 2024
Prepaid expenses and accrued income
Prepaid expenses	9. Prepaid expenses include prepaid R&D costs, administrative costs and employee social obligations totaling CHF 3.9 million and CHF 6.4 million as of June 30, 2024 and December 31, 2023, respectively.

Cash and cash equivalents and s

Cash and cash equivalents and short-term financial assets	6 Months Ended
	Jun. 30, 2024
Cash and cash equivalents and financial assets
Cash and cash equivalents and short-term financial assets	10. The following table summarizes AC Immune’s cash and cash equivalents and short-term financial assets as of June 30, 2024 and December 31, 2023: ​ ​ ​ ​ ​ ​ ​ As of In CHF thousands ​ June 30, 2024 December 31, 2023 Cash and cash equivalents 51,564 78,494 Total cash and cash equivalents 51,564 78,494 ​ ​ ​ ​ ​ ​ ​ As of In CHF thousands ​ June 30, 2024 December 31, 2023 Short-term financial assets due in one year or less 123,560 24,554 Total short-term financial assets 123,560 24,554 ​ For the six months ended June 30, 2024, the net investments associated with the short-term financial assets amounted to CHF 99.0 million, compared to net proceeds associated with the maturity of investments of CHF 38.0 million in the prior comparable period.

Accounts receivable

Accounts receivable	6 Months Ended
	Jun. 30, 2024
Accounts receivable
Accounts receivable	11. As of June 30, 2024, the balance of accounts receivable is nil following the receipt of the CHF 14.8 million milestone payment from Janssen, which was due as of December 31, 2023.

Share capital and Treasury shar

Share capital and Treasury shares	6 Months Ended
	Jun. 30, 2024
Share capital and Treasury shares
Share capital and Treasury shares	12. For a discussion of our at the market offering program with Jefferies LLC for the fiscal year ended December 31, 2023, please refer to Note 12 “Share capital” of our Annual Report on Form 20-F for the year ended December 31, 2023 filed on March 14, 2024. In Q2 2024, the Company issued 5,700,000 registered shares to AC Immune USA, Inc. pursuant to a share agreement, which were subsequently repurchased to be held as treasury shares. In Q2 2024, the Company sold 30,232 common shares previously held as treasury shares pursuant to the Sales Agreement, raising USD 0.1 (CHF 0.1) million, net of underwriting fees. As of June 30, 2024 and December 31, 2023, the Company had 10,902,617 and 5,243,958 treasury shares remaining, respectively.

Finance result, net

Finance result, net	6 Months Ended
	Jun. 30, 2024
Finance result, net
Finance result, net	13. For the three months ended June 30, 2024 and 2023, the net finance result amounted to a loss of CHF 1.8 million and a gain of CHF 0.2 million, respectively. The loss in 2024 is primarily due to unfavorable foreign currency exchange differences related to movement in the CHF versus foreign currencies, predominantly the US Dollar. It is partially offset by an increase in financial income due to higher interest received on net investments in short-term financial assets, attributed to more deposits in 2024 compared to the prior period. For the six months ended June 30, 2024 and 2023, AC Immune recorded CHF 0.4 million and CHF 0.3 million in net financial gains, respectively. The increase in 2024 is primarily related to an increase in financial income due to higher interest received on net investments in short-term financial assets, attributed to more deposits in 2024 compared to the prior period. This is partially offset by unfavorable foreign currency exchange differences related to movement in the CHF versus foreign currencies, predominantly the US Dollar.

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2024
Subsequent events
Subsequent events	14. Management has evaluated subsequent events after the balance sheet date, through the issuance of these Interim Condensed Consolidated Financial Statements, for appropriate accounting and disclosures. The Company has determined that there were no other such events that warrant disclosure or recognition in these Interim Condensed Consolidated Financial Statements.

Basis of preparation and chan_2

Basis of preparation and changes to the Company's accounting policies (Policies)	6 Months Ended
	Jun. 30, 2024
Summary of material accounting policies
Functional and reporting currency	Functional and reporting currency These Interim Condensed Consolidated Financial Statements and accompanying notes are presented in Swiss Francs (CHF), which is AC Immune SA’s functional currency and the Group’s reporting currency. The Company’s subsidiary has a functional currency of the US Dollar (USD). The following exchange rates have been used for the translation of the financial statements of AC Immune USA: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ Year Ended December 31, ​ ​ 2024 2023 ​ 2024 2023 ​ 2023 CHF/USD Closing rate, USD 1 0.909 0.908 0.909 0.908 0.851 Weighted average exchange rate, USD 1 0.914 0.908 0.898 0.921 0.908
Critical judgments and accounting estimates	Critical judgments and accounting estimates The preparation of the Company’s Interim Condensed Consolidated Financial Statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions that affect the amounts reported in the Interim Condensed Consolidated Financial Statements and accompanying notes, and the related application of accounting policies as it relates to the reported amounts of assets, liabilities, income and expenses. The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on Licensing and Collaboration Agreements (LCAs), (ii) clinical development accruals, (iii) net employee defined benefit liability, (iv) share-based compensation, (v) right-of-use assets and lease liabilities and (vi) our IPR&D asset (intangible asset). Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.
Fair value of financial assets and liabilities	Fair value of financial assets and liabilities The Company’s financial assets and liabilities are composed of receivables, short-term financial assets, cash and cash equivalents, trade payables, deferred contract revenue and lease liabilities. The fair value of these financial instruments approximates their respective carrying values due to the short-term maturity of these instruments, and are held at their amortized cost in accordance with IFRS 9, unless otherwise explicitly noted.
Accounting policies, new standards, interpretations and amendments adopted by the Company	Accounting policies, new standards, interpretations and amendments adopted by the Company The accounting policies adopted in the preparation of the Interim Condensed Consolidated Financial Statements are consistent with those followed in the preparation of the Company’s annual consolidated financial statements for the year ended December 31, 2023. As of January 1, 2024 the amendments to paragraphs 69 to 76 of IAS 1, Presentation of Financial Statements (IAS 1), as issued by the IASB became effective. The Company assessed the changes to the accounting standard and determined the amendments had an immaterial impact on the Company’s financial statements. There are no other new IFRS standards, amendments or interpretations that are mandatory as of January 1, 2024 that are relevant to the Company. Additionally, in April 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements (IFRS 18). The new standard on presentation and disclosure in the financial statements will change the structure of the statement of profit or loss, require disclosures for certain profit or loss performance measure that are reported outside of the financial statements, and will enhance principles on aggregation and disaggregation within the notes to the financial statements. This new standard will be effective for annual reporting periods beginning on January 1, 2027 and will require retroactive adoption. The Company is currently evaluating the new standard to determine how it will impact the presentation and disclosure in its financial statements.

Basis of preparation and chan_3

Basis of preparation and changes to the Company's accounting policies (Tables)	6 Months Ended
	Jun. 30, 2024
Summary of material accounting policies
Schedule of exchange rates used for translation of financial statements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ Year Ended December 31, ​ ​ 2024 2023 ​ 2024 2023 ​ 2023 CHF/USD Closing rate, USD 1 0.909 0.908 0.909 0.908 0.851 Weighted average exchange rate, USD 1 0.914 0.908 0.898 0.921 0.908

Contract revenues and other o_2

Contract revenues and other operating income (Tables)	6 Months Ended
	Jun. 30, 2024
Contract revenues and other operating income
Schedule of contract revenues	​ ​ ​ ​ ​ ​ ​ ​ For the Three Months ​ ​ Ended June 30, In CHF thousands, unaudited 2024 2023 Takeda 687 — Total contract revenue 687 — ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months ​ ​ Ended June 30, In CHF thousands, unaudited 2024 2023 Takeda 687 — Total contract revenue 687 —

Loss per share (Tables)

Loss per share (Tables)	6 Months Ended
	Jun. 30, 2024
Loss per share
Schedule of earnings per share	​ ​ ​ ​ ​ ​ ​ For the Three Months ​ ​ Ended June 30, In CHF thousands except for share and per share data 2024 2023 Loss per share (EPS) Numerator Net loss attributable to equity holders of the Company (22,760) (16,833) Denominator Weighted-average number of shares outstanding used to compute EPS basic and diluted attributable to equity holders 99,549,910 84,612,997 Basic and diluted loss per share for the period attributable to equity holders (0.23) (0.20) ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months ​ ​ Ended June 30, In CHF thousands except for share and per share data 2024 ​ 2023 Loss per share (EPS) ​ Numerator ​ Net loss attributable to equity holders of the Company ​ (40,622) (34,346) Denominator ​ ​ ​ Weighted-average number of shares outstanding used to compute EPS basic and diluted attributable to equity holders ​ 99,467,690 83,654,663 Basic and diluted loss per share for the period attributable to equity holders ​ (0.41) (0.41)
Schedule of antidilutive securities	​ ​ ​ ​ ​ ​ ​ For the Three Months ​ ​ Ended June 30, ​ 2024 2023 Share options issued and outstanding 1,578,645 97,875 Restricted share awards subject to future vesting 1,631,911 1,213,703 ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months ​ ​ Ended June 30, ​ ​ 2024 ​ 2023 Share options issued and outstanding 1,659,854 97,875 Restricted share awards subject to future vesting 1,684,826 1,225,175 ​

Property, plant and equipment (

Property, plant and equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Property, plant and equipment.
Schedule of movement in the net book values of property, plant and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2024 ​ ​ ​ IT Lab Leasehold Assets under ​ In CHF thousands ​ Furniture ​ equipment ​ equipment ​ improvements ​ construction ​ Total Acquisition cost: Balance at December 31, 2023 309 2,168 10,233 1,662 — 14,372 Additions 15 45 214 43 — 317 Balance at June 30, 2024 324 2,213 10,447 1,705 — 14,689 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated depreciation: ​ ​ ​ ​ ​ ​ Balance at December 31, 2023 (212) (1,851) (8,101) (832) — (10,996) Depreciation expense (25) (103) (504) (135) — (767) Balance at June 30, 2024 (237) (1,954) (8,605) (967) — (11,763) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying amount: ​ December 31, 2023 97 317 2,132 830 — 3,376 June 30, 2024 87 259 1,842 738 — 2,926 ​

Right-of-use assets, long-ter_2

Right-of-use assets, long-term financial assets and lease liabilities (Tables)	6 Months Ended
	Jun. 30, 2024
Right-of-use assets, long-term financial assets and lease liabilities
Schedule of the movements in the net value book value of right-of-use assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Office IT ​ In CHF thousands ​ Buildings ​ equipment ​ equipment ​ Total Balance as of December 31, 2023 3,446 50 12 3,508 Additions and remeasurements — 64 — 64 Depreciation (318) (12) (7) (337) Balance as of June 30, 2024 3,128 102 5 3,235
Schedule of impact on condensed consolidated statements of income/(loss) and cash flows	​ ​ ​ ​ ​ ​ ​ ​ For the Three Months ​ ​ Ended June 30, In CHF thousands 2024 2023 Statements of income/(loss) Depreciation of right-of-use assets 169 134 Interest expense on lease liabilities 29 24 Expense for short-term leases and leases of low value 170 189 Total 368 347 ​ ​ ​ ​ ​ Statements of cash flows ​ Total cash outflow for leases 372 349 ​ ​ ​ ​ ​ ​ ​ ​ For the Six Months ​ ​ Ended June 30, In CHF thousands 2024 2023 Statements of income/(loss) Depreciation of right-of-use assets 337 269 Interest expense on lease liabilities 59 47 Expense for short-term leases and leases of low value 363 488 Total 759 804 ​ ​ ​ ​ ​ Statements of cash flows ​ Total cash outflow for leases 762 805
Schedule of contractual undiscounted cash flows for lease obligations	​ ​ ​ ​ ​ ​ As of In CHF thousands June 30, 2024 Less than one year 789 1-3 years 1,550 3-5 years 1,155 Total 3,494

Accrued expenses (Tables)

Accrued expenses (Tables)	6 Months Ended
	Jun. 30, 2024
Trade and other payables and accrued expenses
Schedule of accrued expenses	​ ​ ​ ​ ​ ​ ​ As of In CHF thousands ​ June 30, 2024 ​ December 31, 2023 Accrued expenses 11,895 11,087 Total accrued expenses 11,895 11,087

Intangible assets (Tables)

Intangible assets (Tables)	6 Months Ended
	Jun. 30, 2024
Intangible assets
Schedule of net book value of intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2024 ​ As of December 31, 2023 ​ Gross ​ ​ Gross ​ ​ ​ ​ Carrying ​ Accumulated ​ Net Book ​ Carrying ​ Accumulated ​ Net Book In CHF thousands ​ Amount ​ Amortization ​ Value ​ Amount ​ Amortization ​ Value Acquired IPR&D asset ​ 50,416 — 50,416 50,416 — 50,416 Total intangible assets ​ 50,416 — 50,416 50,416 — 50,416

Cash and cash equivalents and_2

Cash and cash equivalents and short-term financial assets (Tables)	6 Months Ended
	Jun. 30, 2024
Cash and cash equivalents and financial assets
Schedule of cash and cash equivalents and short-term financial assets	​ ​ ​ ​ ​ ​ ​ As of In CHF thousands ​ June 30, 2024 December 31, 2023 Cash and cash equivalents 51,564 78,494 Total cash and cash equivalents 51,564 78,494 ​ ​ ​ ​ ​ ​ ​ As of In CHF thousands ​ June 30, 2024 December 31, 2023 Short-term financial assets due in one year or less 123,560 24,554 Total short-term financial assets 123,560 24,554

Corporate information (Details)

Corporate information (Details)	Jun. 30, 2024
Corporate information
Number of technology platforms	2

Basis of preparation and chan_4

Basis of preparation and changes to the Company's accounting policies - Functional and reporting currency (Details) - SFr / $	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Functional and reporting currency
Closing rate, USD 1	0.909	0.908	0.909	0.908	0.851
Weighted average exchange rate, USD 1	0.914	0.908	0.898	0.921	0.908

Basis of preparation and chan_5

Basis of preparation and changes to the Company's accounting policies - Going concern (Details) - CHF (SFr) SFr in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Going concern
Company's cash position	SFr 51,564	SFr 78,494	SFr 40,007	SFr 31,586
Short-term financial assets	SFr 123,560	SFr 24,554

Contract revenues and other o_3

Contract revenues and other operating income (Details) - CHF (SFr) SFr in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract revenue	SFr 687	SFr 687	SFr 0
Takeda
Disclosure of disaggregation of revenue from contracts with customers [line items]
Contract revenue	SFr 687	SFr 687

Contract revenues and other o_4

Contract revenues and other operating income - Anti-Abeta Active Immunotherapy in AD - 2024 agreement Takeda Pharmaceuticals, USA Inc. (Details) SFr in Thousands, $ in Millions	1 Months Ended		3 Months Ended	6 Months Ended
	May 31, 2024 CHF (SFr)	May 31, 2024 USD ($)	Jun. 30, 2024 CHF (SFr)	Jun. 30, 2024 CHF (SFr)	Jun. 30, 2023 CHF (SFr)	May 31, 2024 USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Period to provide notice of termination of agreement	90 days	90 days
Contract revenue			SFr 687	SFr 687	SFr 0
Anti-Abeta Active Immunotherapy in AD – 2024 agreement Takeda Pharmaceuticals, USA, Inc.
Disclosure of disaggregation of revenue from contracts with customers [line items]
Collaborative agreement, upfront payments received	SFr 92,300	$ 100
Transaction price	SFr 92,300					$ 100
Number of development milestones that may occur prior to option exercise included in transaction price	0					0
Contract revenue			687	687
Deferred revenue			SFr 91,600	SFr 91,600
Anti-Abeta Active Immunotherapy in AD – 2024 agreement Takeda Pharmaceuticals, USA, Inc. | License option and development, CMC and regulatory activities
Disclosure of disaggregation of revenue from contracts with customers [line items]
Transaction price	SFr 92,300					$ 100
Anti-Abeta Active Immunotherapy in AD – 2024 agreement Takeda Pharmaceuticals, USA, Inc. | License option
Disclosure of disaggregation of revenue from contracts with customers [line items]
Transaction price	SFr 80,700					87.4
Anti-Abeta Active Immunotherapy in AD – 2024 agreement Takeda Pharmaceuticals, USA, Inc. | Development, CMC and regulatory activities
Disclosure of disaggregation of revenue from contracts with customers [line items]
Number of performance obligations identified	1	1
Transaction price	SFr 11,600					12.6
Anti-Abeta Active Immunotherapy in AD – 2024 agreement Takeda Pharmaceuticals, USA, Inc. | Maximum
Disclosure of disaggregation of revenue from contracts with customers [line items]
Collaborative agreement, potential receivables for option exercise fee and potential development, commercial and sales-based milestones	SFr 1,900,000					$ 2,100

Contract revenues and other o_5

Contract revenues and other operating income - Grants from the Michael J. Fox Foundation (Details) - CHF (SFr) SFr in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Contract revenues
Revenue from contracts with customers	SFr 687		SFr 687	SFr 0
Income from grants	41	SFr 317	109	725
Accrued income	402		402		SFr 246
Grant revenue
Contract revenues
Income from grants	SFr 100	SFr 300	SFr 100	SFr 700

Loss per share (Details)

Loss per share (Details) - CHF (SFr) SFr / shares in Units, SFr in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator
Net loss attributable to equity holders of the Company	SFr (22,760)	SFr (16,833)	SFr (40,622)	SFr (34,346)
Denominator
Weighted-average number of shares outstanding used to compute EPS basic attributable to equity holders	99,549,910	84,612,997	99,467,690	83,654,663
Weighted-average number of shares outstanding used to compute EPS diluted attributable to equity holders	99,549,910	84,612,997	99,467,690	83,654,663
Basic loss per share for the period attributable to equity holders	SFr (0.23)	SFr (0.20)	SFr (0.41)	SFr (0.41)
Diluted loss per share for the period attributable to equity holders	SFr (0.23)	SFr (0.20)	SFr (0.41)	SFr (0.41)

Loss per share - Antidilutive s

Loss per share - Antidilutive securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share options issued and outstanding (in-the-money)
Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [line items]
Number of instruments that are antidilutive in period presented	1,578,645	97,875	1,659,854	97,875
Restricted share awards subject to future vesting
Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [line items]
Number of instruments that are antidilutive in period presented	1,631,911	1,213,703	1,684,826	1,225,175

Property, plant and equipment_2

Property, plant and equipment (Details) SFr in Thousands	6 Months Ended
	Jun. 30, 2024 CHF (SFr)
Property, plant and equipment:
Property, plant and equipment, beginning of period	SFr 3,376
Property, plant and equipment, end of period	2,926
Acquisition Cost
Property, plant and equipment:
Property, plant and equipment, beginning of period	14,372
Additions	317
Property, plant and equipment, end of period	14,689
Accumulated depreciation
Property, plant and equipment:
Property, plant and equipment, beginning of period	(10,996)
Depreciation expense	(767)
Property, plant and equipment, end of period	(11,763)
Furniture
Property, plant and equipment:
Property, plant and equipment, beginning of period	97
Property, plant and equipment, end of period	87
Furniture | Acquisition Cost
Property, plant and equipment:
Property, plant and equipment, beginning of period	309
Additions	15
Property, plant and equipment, end of period	324
Furniture | Accumulated depreciation
Property, plant and equipment:
Property, plant and equipment, beginning of period	(212)
Depreciation expense	(25)
Property, plant and equipment, end of period	(237)
IT Equipment
Property, plant and equipment:
Property, plant and equipment, beginning of period	317
Property, plant and equipment, end of period	259
IT Equipment | Acquisition Cost
Property, plant and equipment:
Property, plant and equipment, beginning of period	2,168
Additions	45
Property, plant and equipment, end of period	2,213
IT Equipment | Accumulated depreciation
Property, plant and equipment:
Property, plant and equipment, beginning of period	(1,851)
Depreciation expense	(103)
Property, plant and equipment, end of period	(1,954)
Lab Equipment
Property, plant and equipment:
Property, plant and equipment, beginning of period	2,132
Property, plant and equipment, end of period	1,842
Lab Equipment | Acquisition Cost
Property, plant and equipment:
Property, plant and equipment, beginning of period	10,233
Additions	214
Property, plant and equipment, end of period	10,447
Lab Equipment | Accumulated depreciation
Property, plant and equipment:
Property, plant and equipment, beginning of period	(8,101)
Depreciation expense	(504)
Property, plant and equipment, end of period	(8,605)
Leasehold Improvements
Property, plant and equipment:
Property, plant and equipment, beginning of period	830
Property, plant and equipment, end of period	738
Leasehold Improvements | Acquisition Cost
Property, plant and equipment:
Property, plant and equipment, beginning of period	1,662
Additions	43
Property, plant and equipment, end of period	1,705
Leasehold Improvements | Accumulated depreciation
Property, plant and equipment:
Property, plant and equipment, beginning of period	(832)
Depreciation expense	(135)
Property, plant and equipment, end of period	SFr (967)

Right-of-use assets, long-ter_3

Right-of-use assets, long-term financial assets and lease liabilities (Details) - CHF (SFr) SFr in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Right-of-use of leased assets:
Balance, beginning of period			SFr 3,508
Additions and remeasurements			64
Depreciation	SFr (169)	SFr (134)	(337)	SFr (269)
Balance, end of period	SFr 3,235		3,235
Variable lease payments that are not included in the measurement of lease obligations			0
Maximum
Right-of-use of leased assets:
Additions and remeasurements			SFr 100
Buildings
Right-of-use assets and lease liabilities:
Weighted average incremental borrowing rate	3.50%		3.50%
Right-of-use of leased assets:
Balance, beginning of period			SFr 3,446
Depreciation			(318)
Balance, end of period	SFr 3,128		SFr 3,128
Office Equipment
Right-of-use assets and lease liabilities:
Weighted average incremental borrowing rate	3.30%		3.30%
Right-of-use of leased assets:
Balance, beginning of period			SFr 50
Additions and remeasurements			64
Depreciation			(12)
Balance, end of period	SFr 102		SFr 102
IT Equipment
Right-of-use assets and lease liabilities:
Weighted average incremental borrowing rate	2.60%		2.60%
Right-of-use of leased assets:
Balance, beginning of period			SFr 12
Depreciation			(7)
Balance, end of period	SFr 5		SFr 5

Right-of-use assets, long-ter_4

Right-of-use assets, long-term financial assets and lease liabilities - Statement of income/(loss) and cash flow (Details) - CHF (SFr) SFr in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statements of income/(loss) and cash flows
Depreciation of right-of-use assets	SFr 169	SFr 134	SFr 337	SFr 269
Interest expense on lease liabilities	29	24	59	47
Expense for short-term leases and leases of low value	170	189	363	488
Total	368	347	759	804
Total cash outflow for leases	SFr 372	SFr 349	SFr 762	SFr 805

Right-of-use assets, long-ter_5

Right-of-use assets, long-term financial assets and lease liabilities - Contractual undiscounted cash flows for lease obligations (Details) - CHF (SFr) SFr in Thousands	Jun. 30, 2024	Dec. 31, 2023
Contractual undiscounted cash flows for lease liabilities:
Contractual undiscounted cash flows for lease obligations	SFr 3,494
Escrow deposits	400	SFr 400
Less than one year
Contractual undiscounted cash flows for lease liabilities:
Contractual undiscounted cash flows for lease obligations	789
1-3 years
Contractual undiscounted cash flows for lease liabilities:
Contractual undiscounted cash flows for lease obligations	1,550
3-5 years
Contractual undiscounted cash flows for lease liabilities:
Contractual undiscounted cash flows for lease obligations	SFr 1,155

Accrued expenses (Details)

Accrued expenses (Details) - CHF (SFr) SFr in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Trade and other payables and accrued expenses
Trade and other payables	SFr 1,435	SFr 1,679
Accrued Expenses	11,895	11,087
Total	SFr 11,895	SFr 11,087	SFr 11,100

Intangible assets (Details)

Intangible assets (Details) - CHF (SFr) SFr in Thousands	Jun. 30, 2024	Dec. 31, 2023
Disclosure of intangible assets material to entity [abstract]
Intangible Assets	SFr 50,416	SFr 50,416
Gross Carrying Amount
Disclosure of intangible assets material to entity [abstract]
Intangible Assets	50,416	50,416
Acquired IPR&D Asset
Disclosure of intangible assets material to entity [abstract]
Intangible Assets	50,416	50,416
Acquired IPR&D Asset | Gross Carrying Amount
Disclosure of intangible assets material to entity [abstract]
Intangible Assets	SFr 50,416	SFr 50,416

Prepaid expenses (Details)

Prepaid expenses (Details) - CHF (SFr) SFr in Thousands	Jun. 30, 2024	Dec. 31, 2023
Prepaid expenses and accrued income
Prepaid expenses	SFr 3,864	SFr 6,437

Cash and cash equivalents and f

Cash and cash equivalents and financial assets - Cash and cash equivalents (Details) SFr in Thousands	Jun. 30, 2024 CHF (SFr) SFr / $	Dec. 31, 2023 CHF (SFr) SFr / $	Jun. 30, 2023 CHF (SFr) SFr / $	Dec. 31, 2022 CHF (SFr)
Cash and cash equivalents [Abstract]
Cash and cash equivalents | SFr	SFr 51,564	SFr 78,494	SFr 40,007	SFr 31,586
Translation rate into CHF | SFr / $	0.909	0.851	0.908

Cash and cash equivalents and_3

Cash and cash equivalents and short-term financial assets - Short-term financial assets (Details) - CHF (SFr) SFr in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Miscellaneous current assets [abstract]
Short-term financial assets due in one year or less	SFr 123,560		SFr 24,554
Proceeds from maturity of short-term financial assets	SFr 99,000	SFr 38,000

Accounts receivable (Details)

Accounts receivable (Details) - CHF (SFr) SFr in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accounts receivable
Accounts receivable	SFr 0	SFr 14,800

Share capital and Treasury sh_2

Share capital and Treasury shares (Details) SFr in Millions, $ in Millions	3 Months Ended
	Jun. 30, 2024 USD ($) shares	Jun. 30, 2024 CHF (SFr) shares	Dec. 31, 2023 shares
Disclosure of classes of share capital [line items]
Number of treasury shares sold during period	30,232	30,232
Proceeds from sale or issue of treasury shares	$ 0.1	SFr 0.1
Number of treasury shares outstanding	10,902,617	10,902,617	5,243,958
AC Immune USA
Disclosure of classes of share capital [line items]
Number of shares issued during the period	5,700,000	5,700,000

Finance results, net (Details)

Finance results, net (Details) - CHF (SFr) SFr in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Finance result, net
Net financial gains (losses)	SFr (1,799)	SFr 216	SFr 407	SFr 277
Finance income associated with change in fair value of derivative financial assets	SFr 739	SFr 259	SFr 1,368	SFr 468